Candel Therapeutics CEO discusses promising Phase 2 pancreatic cancer trial results - ICYMI

Candel Therapeutics Inc (NASDAQ:CADL) CEO Dr Paul Peter Tak talked with Proactive about the encouraging results from the phase 2 trial of its investigational medicine CAN-2409 for borderline resectable pancreatic cancer. Dr Tak shared that the median overall survival in the active treatment group reached 31.4 months, compared to just 12.5 months in the control group, showing a clear separation of survival curves. Three out of seven patients in the treatment group remained alive after prolonged follow-up, wi ...